Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
5 Best Companies for Construction Site Barriers
Construction projects depend on barriers for reasons that go well beyond appearances; they protect workers, push traffic away from danger...
10 Best TV Series Like Stranger Things
Have you also finished watching all five seasons of Stranger Things? And if you are already searching for the best...
Global Trade Is Not Ending — It Is Being Reshaped by Geopolitical Competition
Seaports and container terminals remain essential to international commerce, connecting manufacturers, suppliers and consumers across global markets. Photo: Jonathan Thacker...
The AI Investment Boom: Who Will Capture the Economic Benefits?
Data centres provide the computing infrastructure that supports artificial intelligence, cloud services and the digital economy. Photo: Helpameout / Wikimedia...
How to Recover a Disabled Instagram Account? Tips and Process
Losing access to your personal or business Instagram account can disrupt personal connections, professional outreach, or years of memories. Instagram...
How Payment Processing Fees Affect Ecommerce Profit Margins
Card fees take a larger share of an online store’s profit than its revenue line suggests. Publicly traded general retailers...
